ContractSpecial Notice
Intent to Sole Source - X10 VIALS of Floxuridine 500MG vials
DEPARTMENT OF HEALTH AND HUMAN SERVICES• NOI-CC-OLAO-26-006059
Response Deadline
Jun 3, 2026
14 days left
Days Remaining
14
Until deadline
Set-Aside
No Set aside used
Notice Type
Special Notice
Contract Opportunity Analysis
The NIH Clinical Center within the Department of Health and Human Services is pursuing a sole-source purchase of X10 vials of Floxuridine 500 mg for patient care. The acquisition is for Floxuridine 500 mg vials for injection, identified as a new requirement with an estimated value of $41,770.00. It is justified as other than full and open competition because Cardinal Health dba Specialty Pharmaceutical Services, also referenced as JND Therapeutics, is identified as the sole distributor in the United States, with performance in Bethesda, Maryland. Interested responsible sources may submit a capability statement by email referencing NOI-CC-OLAO-26-006059 no later than 12:00 PM Eastern Standard Time on 06/03/2026 to valerie.gregorio@nih.gov.
Classification Codes
NAICS Code
325412
Pharmaceutical Preparation Manufacturing
PSC Code
6505
DRUGS AND BIOLOGICALS
Solicitation Documents
Quote JND.pdf
PDF•71 KB•May 20, 2026
AI Summary
JND Therapeutics, Inc. announced a price increase for its Floxuridine for Injection, USP, effective January 7th, 2026. The new price for the 500mg/vial product (NDC 81643-9270-1) will be $4,177.00. Customers are advised to update their systems to avoid processing delays and invoice payment issues. For inquiries, Griffith Walters can be contacted at gwalters@jndtherapeutics.com. This notice, relevant for government entities involved in procurement, ensures transparency regarding pharmaceutical costs.
Sole Source Justification Floxuridine-05.2026 (1).docx
Word•45 KB•May 20, 2026
AI Summary
The NIH Clinical Center is requesting a Justification for Other than Full and Open Competition to acquire Floxuridine 500mg vials for patient care. This is a new requirement with an estimated value of $41,770.00. The acquisition is justified under 41 USC 501 and FAR Part 8.405-6 (Federal Supply Schedule, limited competition) because Cardinal Health (dba CERONA, etc.) is the sole distributor of this medication in the United States. The contracting officer determined the anticipated cost to be fair and reasonable based on historical and initial purchase prices. The requestor and the Chief Pharmacy Procurement certified the accuracy and completeness of the justification.
Related Contract Opportunities
Project Timeline
postedOriginal Solicitation PostedMay 20, 2026
deadlineResponse DeadlineJun 3, 2026
expiryArchive DateJun 18, 2026
Agency Information
Department
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Sub-Tier
NATIONAL INSTITUTES OF HEALTH
Place of Performance
Bethesda, Maryland, UNITED STATES